점안제 시장, 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

Ophthalmic Eye Dropper Market size is projected to grow at a 6.7% CAGR from 2024 to 2032, fueled by a surge in product launches and technological advancements.

Companies are unveiling new eye dropper models, emphasizing cutting-edge innovations in precision and user-friendliness. These advancements not only enhance dosing accuracy but also elevate the overall user experience. Furthermore, features like ergonomic designs, tamper-evident packaging, and sophisticated drop control mechanisms are being integrated, making eye care more effective. For instance, in June 2023, Bausch + Lomb Corporation launched its PreserVision AREDS 2 Formula soft gels with CoQ10 in the U.S., broadening the spectrum of ophthalmic solutions and underscoring the industry's commitment to advancing eye health products.

The overall market is segregated into eye dropper type, mode, indication, end-use, and region.

Based on eye dropper type, the ophthalmic eye dropper market value from the unidose eye dropper segment is forecasted to rise at a notable rate from 2024 to 2032. This is attributed to the growing preference for unidose eye droppers for their convenience and precision. By offering single-use applications, these droppers minimize contamination risks and enhance dosing accuracy, ensuring a sterile and user-friendly experience.

Ophthalmic eye dropper industry from the glaucoma indication segment is anticipated to expand at a significant CAGR through 2032. This is largely due to the critical role eye droppers play in managing glaucoma, delivering precise medication doses directly to the eye. By effectively reducing intraocular pressure, these droppers are pivotal in glaucoma management, underscoring their importance in maintaining optimal eye health.

Europe ophthalmic eye dropper market is set for robust growth between 2024 and 2032, driven by the expanding aging population. With the elderly demographic on the rise, there is an escalating demand for effective eye care solutions. Conditions like cataracts, glaucoma, and dry eye syndrome are becoming more prevalent, and eye droppers offer a convenient means to address these challenges. As Europe navigates the evolving needs of its aging population, continued innovations in eye care solutions, including eye droppers, will be paramount.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of eye disorders
    • 3.2.1.2 Technological advancements in ophthalmic drug delivery systems
    • 3.2.1.3 Increasing geriatric population coupled with disease
    • 3.2.1.4 Increasing awareness and diagnosis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Non-compliance and poor adherence
    • 3.2.2.2 Associated side effects and tolerance issues
• 3.3 Growth potential analysis
• 3.4 Volume analysis of preservative-free multi-dose eye dropper, 2018-2032
• 3.5 Regulatory landscape
• 3.6 Technological landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Eye Dropper Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Unidose eye dropper
• 5.3 Preserved multi-dose eye dropper
• 5.4 Preservative-free multi-dose eye dropper

Chapter 6 Market Estimates and Forecast, By Mode, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Prescription drugs
• 6.3 Over the counter (OTC) drugs

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Glaucoma
• 7.3 Allergies
• 7.4 Conjunctivitis
• 7.5 Dry eye
• 7.6 Other indications

Chapter 8 Market Estimates and Forecast, By End-use, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Ophthalmic clinics
• 8.4 Homecare settings
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Alcon Inc.
• 10.3 AdvaCare Pharma
• 10.4 Bausch Health Companies Inc.
• 10.5 Dompe Farmaceutici S.p.A
• 10.6 Novartis AG
• 10.7 Pfizer Inc.
• 10.8 PanOptica, Inc.
• 10.9 Prestige Consumer Healthcare Inc.
• 10.10 Sun Pharmaceutical Industries Ltd.